Intra-arterial bevacizumab (IA BV) has been recently identified to be safe in the treatment of recurrent GBM. In this study, we sought to perform a cost analysis of IA BV versus IV BV especially also taking account of patient progression free survival (PFS) and overall survival (OS). We show that IA BV is significantly more cost effective than conventional IV therapy.
|Original language||English (US)|
|Number of pages||4|
|Journal||Journal of Experimental Therapeutics and Oncology|
|State||Published - Dec 29 2011|
All Science Journal Classification (ASJC) codes
- Drug Discovery
- Cancer Research